Treatment-Resistant Depression (TRD) Dosing and Administration Overview1

TRD Dosing Frequency and Strengths Are Flexible1

  • SPRAVATO® is administered by the patient at a certified treatment center where the patient is monitored by a healthcare provider for at least two hours

SPRAVATO® offers the freedom to choose your treatment approach1

Start with 56 mg or 84 mg, alone or in combination with an oral AD, and an individualized dosing schedule

Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment.

Treatment-Resistant Depression (TRD) Dosing and Administration chart
Treatment-Resistant Depression (TRD) Dosing and Administration chart

Start with 56 mg or 84 mg

  • If clinically warranted, you may start a patient on SPRAVATO® alone — without the need to combine it with an oral AD
  • SPRAVATO® now offers more flexibility in treatment approach, dosing, and post-induction frequency

Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment

injection dosing spray, 56mg or 84mg

AD=antidepressant.

injection dosing spray, 56mg or 84mg

AD=antidepressant.

Administration

SPRAVATO® is the only FDA-approved treatment used alone or in combination with an oral antidepressant for patients with MDD having an inadequate response to at least 2 oral antidepressants1

Monitoring & Discharge

  • To ensure safe and appropriate use, SPRAVATO® nasal spray is administered only at REMS-certified treatment centers
  • After taking SPRAVATO®, patients are monitored and evaluated by a healthcare provider for at least 2 hours until patients are safe to leave
  • Respiratory status (including pulse oximetry) should be monitored at each treatment session
  • Blood pressure should be monitored prior to and 40 minutes after administration and subsequently as clinically warranted until values remain consistent at a safe level and the treatment session ends
  • Patients should coordinate a ride home after treatment, as they should not drive or operate heavy machinery until the next day, following a restful night’s sleep

Careful consideration is advised prior to treatment of individuals with a history of substance use disorder, including alcohol. Monitoring for signs of abuse and dependence is recommended.

AD=antidepressant; MDD=major depressive disorder; REMS=Risk Evaluation and Mitigation Strategy.

References:

  1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.
VIEW FULL IMPORTANT SAFETY INFORMATIONisi-icon